GLP-1 vs Tirzepatide: Which Works Better for Weight Loss?

When patients and providers compare weight loss medications, one question consistently rises to the top: Does tirzepatide outperform traditional GLP-1 agonists like semaglutide?

The answer, based on the most rigorous head-to-head clinical trial data available, is yes—tirzepatide produces significantly greater average weight loss than semaglutide at maximum tolerated doses.

But the full picture is more nuanced, and understanding why matters for making informed treatment decisions.

The Head-to-Head Evidence: SURMOUNT-5

The definitive comparison comes from the SURMOUNT-5 trial, a 72-week, randomized, controlled phase 3b study published in the New England Journal of Medicine. This was the first trial designed specifically to compare tirzepatide (Zepbound) directly against semaglutide (Wegovy) in adults with obesity but without type 2 diabetes .

The Results

The trial enrolled 751 participants across 32 sites in the United States and Puerto Rico. Both groups received identical lifestyle counseling, and both drugs were titrated to their maximum tolerated doses .

The difference was statistically significant and clinically meaningful. Participants on tirzepatide were twice as likely to achieve at least 25% body weight reduction compared to those on semaglutide .

Why Tirzepatide Outperforms: The Dual Mechanism

The performance gap comes down to pharmacology. Semaglutide is a GLP-1 receptor agonist—it activates one hormone pathway that reduces appetite and slows gastric emptying.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway. This dual action appears to produce additive effects on appetite suppression, fat metabolism, and blood sugar regulation .

Think of it as activating two complementary braking systems on appetite and weight gain, rather than just one.

Reinforcing Evidence from Multiple Analyses

The SURMOUNT-5 findings are supported by a growing body of independent research:

Network Meta-Analysis (Endocrine Society 2026): This analysis of phase 3 trials confirmed that tirzepatide 15 mg achieved superior weight reduction compared to semaglutide 2.4 mg in the head-to-head SURMOUNT-5 trial, with a mean difference of −5.8% body weight .

Systematic Review and Meta-Analysis (Cureus): Pooling seven studies with 28,980 participants, researchers found tirzepatide was significantly superior to semaglutide for weight reduction. At six months, the mean difference was 1.33 kg in favor of tirzepatide, with significantly higher odds of achieving ≥10% weight loss .

Real-World Cohort Study (All of Us Research Program): Among 14,046 adults with obesity, tirzepatide was associated with the largest magnitude of weight loss, particularly for achieving high-threshold weight loss of 15% or more .

Updated Systematic Review (Annals of Internal Medicine 2026): Placebo-subtracted weight loss reached −19.0% for tirzepatide compared to −14.8% for subcutaneous semaglutide .

Important Caveats and Context

Semaglutide still ranks highly. In some network meta-analyses, semaglutide 2.4 mg ranks highest overall for weight loss when considering all comparators together, with tirzepatide 15 mg ranking closely behind . The difference between them is real but not enormous—both are highly effective.

Early response predicts success. A SURMOUNT-5 post hoc analysis found that 44% of tirzepatide participants were “rapid responders” (≥15% weight loss by week 24) compared to 21% of semaglutide participants. Rapid responders in both groups achieved greater end-of-study weight reductions .

Cardiovascular data favors semaglutide. While tirzepatide wins on weight loss, semaglutide has proven cardiovascular benefits through the SELECT trial, reducing major adverse cardiovascular events in patients with existing heart disease. Tirzepatide’s cardiovascular outcomes trials are ongoing .

Individual response varies. Some patients respond better to one medication than the other. The choice isn’t purely about average efficacy—it’s about what works for you.

What This Means for Treatment Decisions

The Bottom Line

Tirzepatide produces greater average weight loss than semaglutide—approximately 20% versus 14% of body weight in head-to-head comparison. The dual GIP/GLP-1 mechanism appears to provide an advantage over single GLP-1 activation.

But “better” depends on your goals. Semaglutide offers proven cardiovascular benefits and broader insurance coverage in some settings. Tirzepatide offers superior weight loss efficacy. Talk to a licensed healthcare provider about which option aligns with your medical history, treatment goals, and coverage situation.

This information is for educational purposes only and does not constitute medical advice. Prescription weight loss medications require evaluation by a licensed healthcare provider. Always discuss potential benefits and risks with your doctor.